What Is the Albumin-Creatinine Ratio?
The ACR measures the concentration of albumin (a blood protein) relative to creatinine (a muscle metabolite) in a urine sample. When kidney filtration is compromised, albumin leaks into the urine—a condition called albuminuria. Because creatinine excretion remains relatively stable, using it as a reference normalizes the result for urine dilution, making ACR a reliable marker of kidney damage.
Unlike protein-creatinine ratio measurement, which traditionally required a 24-hour collection, ACR can be determined from a single random or first-morning spot sample. This convenience makes it ideal for routine screening in primary care and for monitoring patients with diabetes, hypertension, or a family history of kidney disease.
The ACR Calculation
The albumin-to-creatinine ratio is calculated by dividing the urine albumin concentration by the urine creatinine concentration, then converting to standardized units (mg/g):
ACR (mg/g) = Albumin (mg) ÷ Creatinine (g) × 1000
Albumin— Urine albumin concentration, typically reported in mg/dL; convert to mg by multiplying by 10 if reading from a lab resultCreatinine— Urine creatinine concentration, typically reported in mg/dL; convert to g/dL by dividing by 100 for use in the formulaACR— The albumin-to-creatinine ratio, expressed in mg/g (milligrams of albumin per gram of creatinine)
Collecting and Interpreting a Urine Sample
Proper sample collection ensures accurate results. Healthcare providers typically request a first-morning urine sample after cleansing the external genitalia. The specimen should be collected mid-stream (discarding the first and last portions) into a sterile container and refrigerated or delivered to the laboratory promptly to prevent bacterial overgrowth or protein degradation.
ACR results are stratified into three categories based on the KDIGO (Kidney Disease: Improving Global Outcomes) albuminuria classification:
- A1 (<30 mg/g): Normal to mildly increased—typical range for those without kidney disease
- A2 (30–300 mg/g): Moderately increased—indicates moderate albuminuria and heightened kidney disease risk
- A3 (>300 mg/g): Severely increased—suggests advanced kidney damage and warrants urgent clinical follow-up
ACR and Chronic Kidney Disease Staging
Chronic kidney disease is staged using two parallel classification systems: glomerular filtration rate (GFR) categories (G1–G5) and albuminuria categories (A1–A3). An elevated ACR (≥30 mg/g) combined with reduced GFR indicates progressive nephron loss and increased cardiovascular risk. Patients with CKD stage A2 albuminuria should receive counselling on blood pressure control, glycaemic management (if diabetic), and regular monitoring to slow disease progression.
Some patients present with albuminuria without significant GFR decline, particularly in early diabetes-related kidney disease. In such cases, intensive management of blood glucose, blood pressure, and lipids can help prevent further deterioration. Regular ACR testing tracks therapeutic response and disease trajectory over months to years.
Practical Considerations for ACR Testing
Key points to bear in mind when ordering, interpreting, or acting on ACR results:
- Single spot sample suffices — A random urine ACR is nearly as predictive as a 24-hour collection. This simplicity improves compliance and enables opportunistic screening in primary care without patient preparation or fasting.
- Recognise transient elevation — Albuminuria can be transiently elevated during acute illness, intense exercise, urinary tract infection, or menstruation in women. Confirm persistently elevated ACR (≥30 mg/g) on at least two occasions weeks apart before diagnosing chronic albuminuria.
- Unit conversion matters — Albumin is typically reported in mg/dL; creatinine in mg/dL or mmol/L. Convert creatinine to g/dL (divide mg/dL by 100) before calculation, or use mmol/L creatinine directly if your lab reports in those units and adjust the formula accordingly.
- ACR alone does not diagnose CKD — An elevated ACR must be contextualised with GFR, blood pressure, blood glucose, and other clinical features. A single mildly elevated result without GFR decline or systemic risk factors may warrant repeat testing rather than immediate treatment initiation.